Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)
Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –
Rallybio cash
Cash and short-term investments held at the end of each period.
Rallybio's cash was $90.70M at Sep 30, 2026. For fiscal 2025 it was $54.70M, down 16.5% from the year before. The highest annual figure on record is $175.33M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.70M | -16.5% |
| FY2024 | Dec 31, 2024 | $65.50M | -40.4% |
| FY2023 | Dec 31, 2023 | $109.90M | -35.0% |
| FY2022 | Dec 31, 2022 | $169.00M | -3.6% |
| FY2021 | Dec 31, 2021 | $175.33M | +25.0% |
| FY2020 | Dec 31, 2020 | $140.23M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $90.70M | +53.0% |
| Q2 FY2026 | Jun 30, 2026 | $92.80M | +103.1% |
| Q1 FY2026 | Mar 31, 2026 | $46.80M | -14.1% |
| Q4 FY2025 | Dec 31, 2025 | $54.70M | -16.5% |
| Q3 FY2025 | Sep 30, 2025 | $59.30M | -21.0% |
| Q2 FY2025 | Jun 30, 2025 | $45.70M | -48.4% |
| Q1 FY2025 | Mar 31, 2025 | $54.50M | -42.1% |
| Q4 FY2024 | Dec 31, 2024 | $65.50M | -40.4% |
| Q3 FY2024 | Sep 30, 2024 | $75.10M | -38.1% |
| Q2 FY2024 | Jun 30, 2024 | $88.60M | -35.7% |
| Q1 FY2024 | Mar 31, 2024 | $94.20M | -37.4% |
| Q4 FY2023 | Dec 31, 2023 | $109.90M | -35.0% |
| Q3 FY2023 | Sep 30, 2023 | $121.40M | -8.3% |
| Q2 FY2023 | Jun 30, 2023 | $137.80M | -6.5% |
| Q1 FY2023 | Mar 31, 2023 | $150.40M | -6.8% |
| Q4 FY2022 | Dec 31, 2022 | $169.00M | -3.6% |
| Q3 FY2022 | Sep 30, 2022 | $132.40M | -29.2% |
| Q2 FY2022 | Jun 30, 2022 | $147.40M | +30.8% |
| Q1 FY2022 | Mar 31, 2022 | $161.40M | +15.1% |
| Q4 FY2021 | Dec 31, 2021 | $175.33M | – |
| Q3 FY2021 | Sep 30, 2021 | $186.98M | – |
| Q2 FY2021 | Jun 30, 2021 | $112.73M | – |
| Q4 FY2020 | Dec 31, 2020 | $140.23M | – |
See a number that looks wrong?